REGN vs. MRNA

Last updated Jun 5, 2026

REGN (Regeneron Pharmaceuticals, Inc.) and MRNA (Moderna, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, REGN returned 4.37%/yr vs -24.19%/yr for MRNA. At a 0.32 correlation, their price movements are largely independent.

Performance

REGN vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Regeneron Pharmaceuticals, Inc. (REGN) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, REGN achieves a -18.32% return, which is significantly lower than MRNA's 74.94% return.

REGN

• 1D: 1.58%
• 1M: -10.34%
• YTD: -18.32%
• 6M: -12.78%
• 1Y: 30.36%
• 3Y*: -5.46%
• 5Y*: 4.37%
• 10Y*: 4.61%

MRNA

• 1D: 5.16%
• 1M: 10.45%
• YTD: 74.94%
• 6M: 102.39%
• 1Y: 89.18%
• 3Y*: -26.31%
• 5Y*: -24.19%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

REGN vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
REGN Regeneron Pharmaceuticals, Inc.	-18.32%	8.96%	-18.90%	21.73%	14.25%	30.72%	28.66%	0.53%	0.18%
MRNA Moderna, Inc.	74.94%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-17.90%

Correlation

The correlation between REGN and MRNA is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.39
Correlation (3Y) Calculated over the trailing 3-year period	0.35
Correlation (5Y) Calculated over the trailing 5-year period	0.35
Correlation (All Time) Calculated using the full available price history since Dec 10, 2018	0.32

Fundamentals

Market Cap REGN : $67.71B MRNA : $20.38B
EPS REGN : $41.05 MRNA : -$8.16
PS Ratio REGN : 4.54 MRNA : 9.07
PB Ratio REGN : 2.15 MRNA : 2.75
Total Revenue (TTM) REGN : $14.92B MRNA : $2.23B
Gross Profit (TTM) REGN : $12.61B MRNA : -$309.00M
EBITDA (TTM) REGN : $5.74B MRNA : -$3.02B

Return for Risk

REGN vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REGN

REGN Risk / Return Rank: 67
REGN Sharpe Ratio Rank: 70
REGN Sortino Ratio Rank: 66
REGN Omega Ratio Rank: 64
REGN Calmar Ratio Rank: 65
REGN Martin Ratio Rank: 72

MRNA

MRNA Risk / Return Rank: 78
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 79
MRNA Omega Ratio Rank: 74
MRNA Calmar Ratio Rank: 79
MRNA Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

REGN vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	REGN	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	0.93	1.40	-0.47
Sortino ratio: Return per unit of downside risk	1.48	2.25	-0.77
Omega ratio: Gain probability vs. loss probability	1.18	1.25	-0.07
Calmar ratio: Return relative to maximum drawdown	1.18	2.53	-1.35
Martin ratio: Return relative to average drawdown	4.09	5.00	-0.91
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

REGN vs. MRNA - Sharpe Ratio Comparison

The current REGN Sharpe Ratio is 0.93, which is lower than the MRNA Sharpe Ratio of 1.40. The chart below compares the historical Sharpe Ratios of REGN and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	REGN	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.93	1.40	-0.47
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.14	-0.37	+0.51
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.14	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.20	-0.04

Drawdowns

REGN vs. MRNA - Drawdown Comparison

The maximum REGN drawdown since its inception was -91.81%, roughly equal to the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for REGN and MRNA.

Drawdown Indicators

	REGN	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-91.81%	-95.38%	+3.57%
Max Drawdown (1Y) Largest decline over 1 year	-25.85%	-35.51%	+9.66%
Max Drawdown (3Y) Largest decline over 3 years	-59.69%	-86.58%	+26.89%
Max Drawdown (5Y) Largest decline over 5 years	-59.69%	-95.38%	+35.69%
Max Drawdown (10Y) Largest decline over 10 years	-59.69%	—	—
Current Drawdown Current decline from peak	-47.25%	-89.35%	+42.10%
Average Drawdown Average peak-to-trough decline	-42.39%	-56.66%	+14.27%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.45%	17.90%	-10.45%

Volatility

REGN vs. MRNA - Volatility Comparison

The current volatility for Regeneron Pharmaceuticals, Inc. (REGN) is 12.54%, while Moderna, Inc. (MRNA) has a volatility of 18.65%. This indicates that REGN experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	REGN	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.54%	18.65%	-6.11%
Volatility (6M) Calculated over the trailing 6-month period	22.39%	48.15%	-25.76%
Volatility (1Y) Calculated over the trailing 1-year period	32.85%	64.07%	-31.22%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	30.77%	66.39%	-35.62%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.16%	71.92%	-39.76%

Dividends

REGN vs. MRNA - Dividend Comparison

REGN's dividend yield for the trailing twelve months is around 0.58%, while MRNA has not paid dividends to shareholders.

Position	TTM	2025
MRNA Moderna, Inc.	0.00%	0.00%
REGN Regeneron Pharmaceuticals, Inc.	0.58%	0.46%

Financials

Frequently Asked Questions

Can I hold both REGN and MRNA in my portfolio?

REGN and MRNA have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, REGN or MRNA?

MRNA has higher volatility (18.65%) compared to REGN (12.54%). In terms of maximum drawdown, REGN dropped -91.81% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.40 vs 0.93), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.